2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation

Journal of Immunology

Volumn 188, Issue 4, 2012, Pages 1847-1855

  Andresen, Lars ^a   Skovbakke, Sarah Line ^a   Persson, Gry ^a   Hagemann Jensen, Michael ^a   Hansen, Karen Aagaard ^a   Jensen, Helle ^a   Skov, Srøen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; MICA; NATURAL KILLER CELL RECEPTOR NKG2D; TUNICAMYCIN;

ARTICLE; CANCER CELL; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GLUCOSE METABOLISM; GLYCOSYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSCRIPTION INITIATION;

CELL LINE, TUMOR; DEOXYGLUCOSE; GLYCOLYSIS; GLYCOSYLATION; HEK293 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTONE DEACETYLASE INHIBITORS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MANNOSE; MEMBRANE PROTEINS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TUNICAMYCIN;

EID: 84856841046     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1004085     Document Type: Article

References (47)

1. Reis e Sousa, C. 2004. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin. Immunol. 16: 27-34.
2. Tesniere, A., T. Panaretakis, O. Kepp, L. Apetoh, F. Ghiringhelli, L. Zitvogel, and G. Kroemer. 2008. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15: 3-12. (Pubitemid 350286167)
3. Kroemer, G., and L. Zitvogel. 2007. Death, danger, and immunity: an infernal trio. Immunol. Rev. 220: 5-7. (Pubitemid 350045576)
4. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. M. Greenberg, and D. H. Raulet. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. [Published erratum appears in 2008 Immunity 28: 723.] Immunity 28: 571-580.
5. González, S., V. Groh, and T. Spies. 2006. Immunobiology of human NKG2D and its ligands. Curr. Top. Microbiol. Immunol. 298: 121-138.
6. López-Larrea, C., B. Suárez-Alvarez, A. López-Soto, A. López-Vázquez, and S. Gonzalez. 2008. The NKG2D receptor: sensing stressed cells. Trends Mol. Med. 14: 179-189.
7. Zitvogel, L., O. Kepp, L. Senovilla, L. Menger, N. Chaput, and G. Kroemer. 2010. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res. 16: 3100-3104.
8. Schilling, D., M. Gehrmann, C. Steinem, A. De Maio, A. G. Pockley, M. Abend, M. Molls, and G. Multhoff. 2009. Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J. 23: 2467-2477.
9. Chan, C. J., D. M. Andrews, N. M. McLaughlin, H. Yagita, S. Gilfillan, M. Colonna, and M. J. Smyth. 2010. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 184: 902-911.
10. Mistry, A. R., and C. A. O'Callaghan. 2007. Regulation of ligands for the activating receptor NKG2D. Immunology 121: 439-447. (Pubitemid 47030096)
11. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
12. Waldhauer, I., D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H. G. Rammensee, and A. Steinle. 2008. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 68: 6368-6376.
13. Kaiser, B. K., D. Yim, I. T. Chow, S. Gonzalez, Z. Dai, H. H. Mann, R. K. Strong, V. Groh, and T. Spies. 2007. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486. (Pubitemid 46816733)
14. Skov, S., M. T. Pedersen, L. Andresen, P. T. Straten, A. Woetmann, and N. Odum. 2005. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65: 11136-11145. (Pubitemid 41713385)
15. Fuertes, M. B., M. V. Girart, L. L. Molinero, C. I. Domaica, L. E. Rossi, M. M. Barrio, J. Mordoh, G. A. Rabinovich, and N. W. Zwirner. 2008. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J. Immunol. 180: 4606-4614.
16. Nice, T. J., W. Deng, L. Coscoy, and D. H. Raulet. 2010. Stress-regulated targeting of the NKG2D ligand Mult1 by a membrane-associated RING-CH family E3 ligase. J. Immunol. 185: 5369-5376.
17. Wu, J., N. J. Chalupny, T. J. Manley, S. R. Riddell, D. Cosman, and T. Spies. 2003. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J. Immunol. 170: 4196-4200. (Pubitemid 36428185)
18. Dunn, C., N. J. Chalupny, C. L. Sutherland, S. Dosch, P. V. Sivakumar, D. C. Johnson, and D. Cosman. 2003. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J. Exp. Med. 197: 1427-1439. (Pubitemid 36682542)
19. Welte, S. A., C. Sinzger, S. Z. Lutz, H. Singh-Jasuja, K. L. Sampaio, U. Eknigk, H. G. Rammensee, and A. Steinle. 2003. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 33: 194-203. (Pubitemid 36157657)
20. Simons, A. L., D. M. Mattson, K. Dornfeld, and D. R. Spitz. 2009. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J. Cancer Res. Ther. 5(Suppl 1): S2-S6.
21. Shutt, D. C., M. S. O'Dorisio, N. Aykin-Burns, and D. R. Spitz. 2010. 2-deoxy- D-glucose induces oxidative stress and cell killing in human neuroblastoma cells. Cancer Biol. Ther. 9: 853-861.
22. Sinthupibulyakit, C., W. Ittarat, W. H. St Clair, and D. K. St Clair. 2010. p53 Protects lung cancer cells against metabolic stress. Int. J. Oncol. 37: 1575-1581.
23. Kurtoglu, M., J. C. Maher, and T. J. Lampidis. 2007. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid. Redox Signal. 9: 1383-1390. (Pubitemid 47255017)
24. Benjamin, L., L. Cassimeris, V. Lingappa, and G. Plopper. 2007. Cells. Jones and Bartlett Publishers, Sudbury, MA.
25. Fares, F. 2006. The role of O-linked and N-linked oligosaccharides on the structure-function of glycoprotein hormones: development of agonists and antagonists. Biochim. Biophys. Acta 1760: 560-567.
26. Marcos, N. T., A. Magalhães, B. Ferreira, M. J. Oliveira, A. S. Carvalho, N. Mendes, T. Gilmartin, S. R. Head, C. Figueiredo, L. David, et al. 2008. Helicobacter pylori induces beta3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl-Lewis x. J. Clin. Invest. 118: 2325-2336.
27. Lantéri, M., V. Giordanengo, N. Hiraoka, J. G. Fuzibet, P. Auberger, M. Fukuda, L. G. Baum, and J. C. Lefebvre. 2003. Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology 13: 909-918. (Pubitemid 37508894)
28. Kobata, A., and J. Amano. 2005. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol. Cell Biol. 83: 429-439. (Pubitemid 41044621)
29. Andresen, L., H. Jensen, M. T. Pedersen, K. A. Hansen, and S. Skov. 2007. Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells. J. Immunol. 179: 8235-8242.
30. Cloos, P. A., J. Christensen, K. Agger, A. Maiolica, J. Rappsilber, T. Antal, K. H. Hansen, and K. Helin. 2006. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442: 307-311. (Pubitemid 44114906)
31. Ashiru, O., N. J. Bennett, L. H. Boyle, M. Thomas, J. Trowsdale, and M. R. Wills. 2009. NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J. Virol. 83: 12345-12354.
32. Chevallet, M., H. Diemer, A. Van Dorssealer, C. Villiers, and T. Rabilloud. 2007. Toward a better analysis of secreted proteins: the example of the myeloid cells secretome. Proteomics 7: 1757-1770. (Pubitemid 46910996)
33. Andresen, L., K. A. Hansen, H. Jensen, S. F. Pedersen, P. Stougaard, H. R. Hansen, J. Jurlander, and S. Skov. 2009. Propionic acid secreted from propionibacteria induces NKG2D ligand expression on human-activated T lymphocytes and cancer cells. J. Immunol. 183: 897-906.
34. Armeanu, S., M. Bitzer, U. M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, et al. 2005. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65: 6321-6329. (Pubitemid 40994418)
35. Valés-Gómez, M., S. E. Chisholm, R. L. Cassady-Cain, P. Roda-Navarro, and H. T. Reyburn. 2008. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 68: 1546-1554. (Pubitemid 351346864)
36. Groh, V., A. Bruhl, H. El-Gabalawy, J. L. Nelson, and T. Spies. 2003. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 100: 9452-9457. (Pubitemid 37033949)
37. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190. (Pubitemid 41232299)
38. Groh, V., S. Bahram, S. Bauer, A. Herman, M. Beauchamp, and T. Spies. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93: 12445-12450. (Pubitemid 26367163)
39. Venkataraman, G. M., D. Suciu, V. Groh, J. M. Boss, and T. Spies. 2007. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J. Immunol. 178: 961-969. (Pubitemid 46095169)
40. Spreu, J., T. Stehle, and A. Steinle. 2006. Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains. J. Immunol. 177: 3143-3149. (Pubitemid 44277832)
41. Li, P., S. T. Willie, S. Bauer, D. L. Morris, T. Spies, and R. K. Strong. 1999. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity 10: 577-584. (Pubitemid 29262660)
42. Shankar, S., and R. K. Srivastava. 2008. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv. Exp. Med. Biol. 615: 261-298.
43. Cao, X., L. Fang, S. Gibbs, Y. Huang, Z. Dai, P. Wen, X. Zheng, W. Sadee, and D. Sun. 2007. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother. Pharmacol. 59: 495-505. (Pubitemid 46122328)
44. Egler, V., S. Korur, M. Failly, J. L. Boulay, R. Imber, M. M. Lino, and A. Merlo. 2008. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin. Cancer Res. 14: 3132-3140.
45. Nückel, H., M. Switala, L. Sellmann, P. A. Horn, J. Dürig, U. Dührsen, R. Küppers, H. Grosse-Wilde, and V. Rebmann. 2010. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 24: 1152-1159.
46. Paschen, A., A. Sucker, B. Hill, I. Moll, M. Zapatka, X. D. Nguyen, G. C. Sim, I. Gutmann, J. Hassel, J. C. Becker, et al. 2009. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin. Cancer Res. 15: 5208-5215.
47. Wu, J. D., L. M. Higgins, A. Steinle, D. Cosman, K. Haugk, and S. R. Plymate. 2004. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114: 560-568. (Pubitemid 39572106)